Citation profile for Katharina Elisabeth Blankart

Katharina Elisabeth Blankart : Citation Profile

Universität Duisburg-Essen (95% share)
Universität Hamburg (5% share)

H index

i10 index

Citations

RESEARCH PRODUCTION:

Articles

Papers

RESEARCH ACTIVITY:

   11 years (2011 - 2022). See details.
   Cites by year: 3
   Journals where Katharina Elisabeth Blankart has often published
   Relations with other researchers
   Recent citing documents: 12.    Total self citations: 13 (26 %)

MORE DETAILS IN:

EconPapers Author's homepage

ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pfi221
   Updated: 2023-05-27    RAS profile: 2022-09-14
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Lichtenberg, Frank (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Katharina Elisabeth Blankart.

Is cited by:

LEVAGGI, ROSELLA (3)

Mortimer, Duncan (2)

Lancsar, Emily (2)

Gu, Yuanyuan (2)

Blankart, Carl (1)

Wichardt, Philipp (1)

Fernandez, Jose Luis (1)

Ma, Ching-to (1)

Hu, Min (1)

Lippi Bruni, Matteo (1)

Leidl, Reiner (1)

Cites to:

Devlin, Nancy (10)

Leidl, Reiner (8)

Lichtenberg, Frank (7)

Stargardt, Tom (7)

Parkin, David (7)

Belotti, Federico (5)

Depalo, Domenico (5)

Anell, Anders (5)

Atella, Vincenzo (5)

Schreyögg, Jonas (4)

Main data

Where Katharina Elisabeth Blankart has published?

Journals with more than one article published	# docs
Health Policy	6
The European Journal of Health Economics	3
IJERPH	2

Recent works citing Katharina Elisabeth Blankart (2022 and 2021)

Year	Title of citing document
2021	Regulatory and HTA early dialogues in medical devices. (2021). Blankart, Carl ; Penton, Hannah ; Dams, Florian ; Federici, Carlo ; Iskandar, Rowan ; Shatrov, Kosta ; Zemplenyi, Antal ; Kalo, Zoltan. In: Health Policy. RePEc:eee:hepoli:v:125:y:2021:i:10:p:1322-1329. Full description at Econpapers \|\| Download paper
2022	How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. (2022). Kanavos, Panos ; Mills, Mackenzie. In: Health Policy. RePEc:eee:hepoli:v:126:y:2022:i:11:p:1130-1143. Full description at Econpapers \|\| Download paper
2022	Promoting innovation while controlling cost: The UKs approach to health technology assessment. (2022). Mossialos, Elias ; Carter, Paul ; McGuire, Alistair ; Taylor, David ; Drummond, Michael ; Anderson, Michael. In: Health Policy. RePEc:eee:hepoli:v:126:y:2022:i:3:p:224-233. Full description at Econpapers \|\| Download paper
2022	Adherence during COVID-19: The role of aging and socio-economics status in shaping drug utilization. (2022). LEVAGGI, ROSELLA ; Montefiori, Marcello ; Leporatti, Lucia ; di Novi, Cinzia. In: Journal of Economic Behavior & Organization. RePEc:eee:jeborg:v:204:y:2022:i:c:p:1-14. Full description at Econpapers \|\| Download paper
2022	The same old medicine but cheaper: The impact of patent expiry on physicians’ prescribing behaviour. (2022). Lippi Bruni, Matteo ; Mammi, Irene ; Fiorentini, Gianluca. In: Journal of Economic Behavior & Organization. RePEc:eee:jeborg:v:204:y:2022:i:c:p:37-68. Full description at Econpapers \|\| Download paper
2023	Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms: cross-country evidence from weighted-average least squares estimation. (2022). Czypionka, Thomas ; Rohrling, Gerald ; Reiss, Miriam ; Pock, Markus ; Berger, Michael. In: LSE Research Online Documents on Economics. RePEc:ehl:lserod:116928. Full description at Econpapers \|\| Download paper
2021	. Full description at Econpapers \|\| Download paper
2022	. Full description at Econpapers \|\| Download paper
2021	Beyond price: the effects of non-financial barriers on access to drugs and health outcomes. (2021). LEVAGGI, ROSELLA ; Montefiori, Marcello ; Leporatti, Lucia. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:22:y:2021:i:4:d:10.1007_s10198-021-01270-8. Full description at Econpapers \|\| Download paper
2022	The effects of dynamic and static competition on prescription drug prices in Denmark, 1997–2017. (2022). Lichtenberg, Frank R. In: Journal of Evolutionary Economics. RePEc:spr:joevec:v:32:y:2022:i:4:d:10.1007_s00191-022-00777-4. Full description at Econpapers \|\| Download paper
2022	Technology adoption by primary care physicians. (2022). Ma, Ching-to ; Iversen, Tor. In: Health Economics. RePEc:wly:hlthec:v:31:y:2022:i:3:p:443-465. Full description at Econpapers \|\| Download paper
2021	Arzneimittelmarkt-Steuerung unter dem Einfluss von AMNOG und Festbeträgen: Forschungsprojekt im Auftrag der Bristol-Myers Squibb GmbH & Co. KGaA. (2021). Bauer, Cosima ; Giulini-Limbach, Chiara ; May, Uwe. In: IBES Diskussionsbeiträge. RePEc:zbw:udewwd:232. Full description at Econpapers \|\| Download paper

Works by Katharina Elisabeth Blankart:

Year	Title	Type	Cited
2021	A Hard Look at “Soft” Cost?control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany In: CINCH Working Paper Series (since 2020). [Full Text][Citation analysis]	paper	0
	.() In: . [Full Text][Citation analysis] This paper has another version. Agregated cites: 0	paper
2011	A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention In: Health Policy. [Full Text][Citation analysis]	article	1
2012	A systematic review of coverage decision-making on health technologies—Evidence from the real world In: Health Policy. [Full Text][Citation analysis]	article	9
2013	Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis In: Health Policy. [Full Text][Citation analysis]	article	4
2016	Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia In: Health Policy. [Full Text][Citation analysis]	article	8
2016	Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark In: Health Policy. [Full Text][Citation analysis]	article	0
2016	Dispensing behaviour of pharmacies in prescription drug markets In: Health Policy. [Full Text][Citation analysis]	article	0
	In: . [Full Text][Citation analysis]	article	0
	In: . [Full Text][Citation analysis]	article	0
2020	Are patients more adherent to newer drugs? In: Health Care Management Science. [Full Text][Citation analysis]	article	2
2022	The Effects of Off-label Drug Use on Disability and Medical Expenditure In: NBER Working Papers. [Full Text][Citation analysis]	paper	0
2013	Link between Process and Appraisal in Coverage Decisions In: Medical Decision Making. [Full Text][Citation analysis]	article	0
2014	Early Benefit Assessment of Pharmaceuticals in Germany In: Medical Decision Making. [Full Text][Citation analysis]	article	4
2014	Analysing coverage decision-making: opening Pandora’s box? In: The European Journal of Health Economics. [Full Text][Citation analysis]	article	1
2016	The diffusion of generics after patent expiry in Germany In: The European Journal of Health Economics. [Full Text][Citation analysis]	article	3
2018	The impact of physician-level drug budgets on prescribing behavior In: The European Journal of Health Economics. [Full Text][Citation analysis]	article	3
2022	Arzneimittel: Placebo bei Engpassbekämpfung In: Wirtschaftsdienst. [Full Text][Citation analysis]	article	0
2021	Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe In: REGION. [Full Text][Citation analysis]	article	0
2020	The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany In: Health Economics. [Full Text][Citation analysis]	article	2